$101.7 M

VBIV Mkt cap, 04-Dec-2018

$259 K

VBI Vaccines Revenue Q3, 2018
VBI Vaccines Gross profit (Q3, 2018)-542 K
VBI Vaccines Gross profit margin (Q3, 2018), %(209.3%)
VBI Vaccines Net income (Q3, 2018)-15.4 M
VBI Vaccines EBIT (Q3, 2018)-14.5 M
VBI Vaccines Cash, 30-Sep-201826 M

VBI Vaccines Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

548.0k865.0k

Cost of goods sold

3.7m5.2m

Gross profit

(3.1m)(4.3m)

Gross profit Margin, %

(570%)(500%)

Sales and marketing expense

2.6m

R&D expense

3.2m7.1m10.0m20.9m

Operating expense total

2.6m3.2m7.1m25.4m38.1m

EBIT

(13.2m)(13.2m)(24.8m)(37.3m)

EBIT margin, %

(4535%)(4310%)

Interest expense

23.0k957.8k357.4k324.0k2.9m

Interest income

3.0k1.2k

Pre tax profit

(1.5m)

Income tax expense

1.8m431.0k

Net Income

(1.5m)(14.4m)(13.9m)(23.2m)(39.0m)

Quarterly

USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

127.0k344.0k193.0k178.0k234.0k259.0k

Cost of goods sold

1.3m1.4m1.3m1.4m1.1m801.0k

Gross profit

(1.1m)(1.0m)(1.1m)(1.2m)(833.0k)(542.0k)

Gross profit Margin, %

(904%)(294%)(591%)(694%)(356%)(209%)

R&D expense

4.7m4.5m5.2m7.0m10.9m10.5m

General and administrative expense

4.0m3.5m

Operating expense total

9.0m8.7m(9.3m)11.8m16.0m14.8m

EBIT

(8.8m)(8.3m)(9.1m)(11.6m)(15.7m)(14.5m)

EBIT margin, %

(6966%)(2416%)(4736%)(6530%)(6724%)(5615%)

Interest expense

704.0k743.0k742.0k

Income tax expense

431.0k

Net Income

(8.6m)(9.0m)(9.8m)(12.3m)(16.7m)(15.4m)

VBI Vaccines Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

6.7m12.6m32.3m67.7m

Accounts Receivable

10.0k143.0k

Inventories

830.0k788.0k

Current Assets

34.4m70.4m

PP&E

106.5k115.5k1.9m2.2m

Goodwill

8.4m9.0m

Total Assets

19.8m104.8m145.7m

Accounts Payable

650.1k1.2m2.0m1.8m

Short-term debt

700.0k375.0k900.0k

Current Liabilities

7.6m13.2m

Long-term debt

700.0k

Non-Current Liabilities

13.4m12.6m

Total Debt

1.4m

Common Stock

2.0k2.5k133.3m

Additional Paid-in Capital

79.1m86.6m58.6m60.9m

Retained Earnings

9.1m(69.5m)(83.4m)(105.0m)(144.0m)

Total Equity

13.0m83.7m119.8m

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.5 x1.3 x1.2 x

VBI Vaccines Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(1.5m)(14.4m)(13.9m)(23.2m)(39.0m)

Depreciation and Amortization

18.9k606.0k730.0k

Accounts Receivable

113.0k(127.0k)

Inventories

(93.0k)(89.0k)

Accounts Payable

11.0k(675.0k)

Cash From Operating Activities

2.7m

Purchases of PP&E

(112.3k)(77.8k)(585.0k)(640.0k)

Cash From Investing Activities

(20.4k)

Long-term Borrowings

(42.6k)(375.0k)

Cash From Financing Activities

3.7m

Interest Paid

145.0k357.4k283.0k1.9m

Quarterly

USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(8.6m)(17.7m)(27.5m)(12.3m)(29.0m)(44.3m)

Depreciation and Amortization

171.0k353.0k539.0k149.0k288.0k417.0k

Accounts Receivable

(32.0k)(212.0k)13.0k

Inventories

(78.0k)17.0k198.0k(286.0k)(373.0k)

Accounts Payable

(609.0k)49.0k614.0k946.0k1.3m

Purchases of PP&E

(266.0k)(422.0k)(526.0k)(1.0m)(2.0m)(3.6m)

Cash From Investing Activities

(3.6m)

Interest Paid

450.0k906.0k1.4m

VBI Vaccines Ratios

USDY, 2018

Financial Leverage

1.4 x
Report incorrect company information

VBI Vaccines Employee Rating

00 votes
Culture & Values
N/A
Work/Life Balance
N/A
Senior Management
N/A
Salary & Benefits
N/A
Career Opportunities
N/A
Source